Game Plan Financial Advisors’s Rein Therapeutics RNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-25
Closed -$44 384
2025
Q1
$44 Hold
25
﹤0.01% 351
2024
Q4
$56 Hold
25
﹤0.01% 363
2024
Q3
$89 Hold
25
﹤0.01% 373
2024
Q2
$69 Sell
25
-25
-50% -$103 ﹤0.01% 368
2024
Q1
$332 Hold
50
﹤0.01% 400
2023
Q4
$152 Buy
+50
New +$97 ﹤0.01% 423
2022
Q4
Sell
-5,000
Closed -$21K 103
2022
Q3
$21K Sell
5,000
-150
-3% -$634 0.02% 84
2022
Q2
$27K Buy
5,150
+500
+11% +$4.59K 0.02% 90
2022
Q1
$48K Buy
4,650
+250
+6% +$2.26K 0.03% 98
2021
Q4
$50K Sell
4,400
-1,950
-31% -$30.2K 0.03% 102
2021
Q3
$130K Buy
6,350
+1,350
+27% +$29.6K 0.08% 93
2021
Q2
$125K Buy
5,000
+1,125
+29% +$28.1K 0.07% 95
2021
Q1
$112K Buy
3,875
+450
+13% +$15.4K 0.07% 92
2020
Q4
$71K Buy
+3,425
New +$85.6K 0.05% 89
2020
Q3
Sell
-3,170
Closed -$75K 76
2020
Q2
$75K Buy
3,170
+75
+2% +$1.22K 0.11% 52
2020
Q1
$20K Buy
3,095
+600
+24% +$7.23K 0.02% 83
2019
Q4
$29K Buy
+2,495
New +$24.6K 0.03% 93

Other funds holding RNTX

Game Plan Financial Advisors's RNTX Position: Q2 2025 in Review

Game Plan Financial Advisors sold out of Rein Therapeutics (RNTX) in Q2 2025, closing a stake of 25 shares — an estimated $44 sold.

Game Plan Financial Advisors first reported a position in RNTX in Q4 2019 and held it in 17 quarters. The position peaked at $130K in Q3 2021. 36 funds tracked by Wall St. Rank hold RNTX as of Q2 2025.

  • Game Plan Financial Advisors reported no remaining Rein Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Game Plan Financial Advisors sold 25 Rein Therapeutics shares in Q2 2025, an estimated $44.
  • Game Plan Financial Advisors first reported a position in Rein Therapeutics in Q4 2019 and held it in 17 quarters.
  • Game Plan Financial Advisors's Rein Therapeutics position peaked at $130K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2025.

Based on Game Plan Financial Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.